GA-BIOLOG-ID
12.9.2019 14:32:07 CEST | Business Wire | Press release
Biolog-id LLC, a developer of end-to-end blood safety solutions and a leader in connected health solutions, announced today that it’s expanding its partnership with University of Cincinnati’s Hoxworth Blood Center to include the management of Red Blood Cell Concentrates, the most commonly requested blood product, in its cutting-edge technology ecosystem across its enterprise.
The expanded partnership, aimed at improving the lives of patients requiring transfusions, leverages Biolog-id patented technology within Hoxworth facilities. The technology, Biolog-Transfusion® , tracks blood products throughout the supply chain, providing real-time visibility into inventory across locations, and collecting data, allowing for comprehensive analysis. This is the first expansion following the appointment of Troy Hilsenroth to CEO of Biolog-id LLC.
“I am thrilled to be expanding our partnership with Hoxworth Blood Center, a trusted organization within the industry, as we expand and grow Biolog-id’s North American presence,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “With Hoxworth, we are committed to helping them achieve their vision by driving operational value and increasing clinical quality through our differentiated platform.”
Hoxworth Blood Center collects, tests, processes and distributes lifesaving blood to 31 hospitals and medical centers in Ohio, Kentucky and Indiana. The blood management ecosystem implemented at Hoxworth allows for the seamless addition of Red Blood Cells with a significant reduction of workload associated with the daily management of inventory and supports better data-driven decisions around the fulfilment of requests from the different hospitals.
"Our partnership with Biolog-id furthers our commitment to embracing innovative technologies to provide a reliable, safe supply of high value blood products to our patients,” said Jose A. Cancetas, Director of Hoxworth Blood Center. "The implementation of Biolog-id’s platform greatly improves the management and distribution of Platelet Concentrates and Red Blood Cell Concentrates as we look to maximize patient outcomes. We are excited for the expansion of our partnership to implement its innovative solutions across our enterprise.”
Biolog-id will be launching an additional pilot program in North America in Q4 2019 focused on the installation of its technology across another major healthcare network.
About Biolog-id
Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has over 100 employees worldwide. Biolog-id is owned by its founder, managers and the Xerys Funds.
Company URL : www.biolog-id.com
About Hoxworth Blood Center
Hoxworth Blood Center, University of Cincinnati was founded in 1938 and serves 31 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky and Southeastern Indiana. Annually, Hoxworth collects more than 80,000 units of blood from local donors to help save the lives of patients in area hospitals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer16.2.2026 10:00:00 CET | Press release
K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep expertise in leading complex, multi-market organisations and has successfully scaled $800M+ P&Ls, working closely with boards, sponsors, and executive leadership teams across the USA, UK, Europe, the Middle East, and APAC. Most recently, Srinivas served as Chief Business Officer and a member of the Executive Council at LTIMindtree, where he was accountable for growth acceleration, market expansion, strategic customer relationships, and operating performance across a highly complex regional footprint. During his tenure, he played a pivotal role in strengthening go-to-market execution, driving margin
Italy Sees Economic Boost From the Opening Weekend of the Olympic Winter Games Milano Cortina 202616.2.2026 09:00:00 CET | Press release
Northern Italy sees more than 60% increase in Visa cardholder visitors from overseas, with an increase in purchases up 80% compared to the same period in 2025 Significant increase in spending from Visa cardholders in many areas of commerce including Clothing & Accessories, Restaurants and Mobility & Transport Biggest share of spend comes from U.S. Visa cardholders, with most significant increases in year-on-year spending from Canada and Switzerland Visa, the Official Payment Technology Partner of the Olympic and Paralympic Winter Games, today released new data revealing consumer spending patterns in the Winter Games host locations1 during the opening weekend of the Olympic Winter Games Milano Cortina 2026. VisaNet data analysed by Visa Consulting & Analytics (VCA) shows the positive impact that Milano Cortina 2026 is having on commerce: Overseas Visa cardholders visits rose by more than 60%, with the largest share of visitors coming from the U.S. (+160% year-on-year), followed by China
Klarna Launches on Google Pay in the UK16.2.2026 09:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, is now available on Google Pay in the UK. Google Pay users in the U.K. can choose Klarna’s interest-free payment options at checkout. Raji Behal, Head of Western and Southern Europe, UK & Ireland at Klarna, said, “We’re really excited to bring Klarna’s fair, flexible and interest-free payment options to Google Pay users. This is a big moment for us and a major step towards our goal of being available at every checkout, everywhere. Together with Google, we’re making it easier than ever for millions of shoppers to choose Klarna and pay in a smarter, more transparent way — all from their phone.” Lisa Yokoyama, Director of Product Management at Google Paysaid: "Expanding our collaboration with Klarna to the U.K. underscores our goal to empower more people with the flexibility to pay how they choose. With people shopping on Google over a billion times a day, this broader footprint provides even more checkout options to help bus
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday16.2.2026 08:00:00 CET | Press release
A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous (IV) infliximab induction helps patients with Crohn’s disease (CD) and ulcerative colitis (UC) recapture and maintain disease control1The results demonstrated that SC infliximab provides an effective and safe option to regain clinical control after a planned or unplanned treatment interruptionMore than a total of 30 accepted abstracts including one oral and one digital oral presentation and eight posters, reinforce Celltrion’s commitment to inflammatory bowel disease (IBD) research aimed at enhancing patient outcomes Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustai
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom